Impact of capsid modifications by selected peptide ligands on recombinant adeno-associated virus serotype 2-mediated gene transduction

Journal of General Virology

Volumn 93, Issue PART 10, 2012, Pages 2131-2141

  Naumer, Matthias ^a   Popa Wagner, Ruth ^a   Kleinschmidt, Jürgen A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ARTICLE; CELL SURFACE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; NONHUMAN; PEPTIDE LIBRARY; PRIORITY JOURNAL; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

CAPSID; CAPSID PROTEINS; CELL LINE, TUMOR; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HEK293 CELLS; HUMANS; LIGANDS; MELANOMA; PEPTIDE LIBRARY; PEPTIDES; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

ADENO-ASSOCIATED VIRUS; MIRIDAE;

EID: 84866313008     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.044735-0     Document Type: Article

References (38)

1. Bartel, M. A., Weinstein, J. R. & Schaffer, D. V. (2012). Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther 19, 694-700.
2. Bartlett, J. S., Wilcher, R. & Samulski, R. J. (2000). Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 74, 2777-2785.
3. Daya, S. & Berns, K. I. (2008). Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21, 583-593.
4. Ding, W., Zhang, L., Yan, Z. & Engelhardt, J. F. (2005). Intracellular trafficking of adeno-associated viral vectors. Gene Ther 12, 873-880.
5. Duan, D., Yue, Y., Yan, Z., Yang, J. & Engelhardt, J. F. (2000). Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 105, 1573-1587.
6. Ferrari, F. K., Samulski, T., Shenk, T. & Samulski, R. J. (1996). Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 70, 3227-3234.
7. Fisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F. & Wilson, J. M. (1996). Transduction with recombinant adenoassociated virus for gene therapy is limited by leading-strand synthesis. J Virol 70, 520-532.
8. Grimm, D., Kern, A., Pawlita, M., Ferrari, F., Samulski, R. & Kleinschmidt, J. (1999). Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther 6, 1322-1330.
9. Hauswirth, W. W., Lewin, A. S., Zolotukhin, S. & Muzyczka, N. (2000). Production and purification of recombinant adeno-associated virus. Methods Enzymol 316, 743-761.
10. Heilbronn, R. &Weger, S. (2010). Viral vectors for gene transfer: current status of gene therapeutics. Handb Exp Pharmacol 197, 143-170.
11. Johnson, J. S. & Samulski, R. J. (2009). Enhancement of adenoassociated virus infection by mobilizing capsids into and out of the nucleolus. J Virol 83, 2632-2644.
12. Johnson, J. S., Li, C., DiPrimio, N., Weinberg, M. S., McCown, T. J. & Samulski, R. J. (2010). Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol 84, 8888-8902.
13. Karcher, S., Steiner, H. H., Ahmadi, R., Zoubaa, S., Vasvari, G., Bauer, H., Unterberg, A. & Herold-Mende, C. (2006). Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 118, 2182-2189.
14. Kay, M. A. (2011). State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 12, 316-328.
15. Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A. & Kleinschmidt, J. A. (2003). Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 77, 11072-11081.
16. Kronenberg, S., Böttcher, B., von der Lieth, C. W., Bleker, S. & Kleinschmidt, J. A. (2005). A conformational change in the adenoassociated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol 79, 5296-5303.
17. Lux, K., Goerlitz, N., Schlemminger, S., Perabo, L., Goldnau, D., Endell, J., Leike, K., Kofler, D. M., Finke, S. & other authors (2005). Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking. J Virol 79, 11776-11787.
18. Michelfelder, S. & Trepel, M. (2009). Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet 67, 29-60.
19. Michelfelder, S., Lee, M. K., deLima-Hahn, E., Wilmes, T., Kaul, F., Müller, O., Kleinschmidt, J. A. & Trepel, M. (2007). Vectors selected from adeno-associated viral display peptide libraries for leukemia celltargeted cytotoxic gene therapy. Exp Hematol 35, 1766-1776.
20. Michelfelder, S., Kohlschütter, J., Skorupa, A., Pfennings, S., Müller, O., Kleinschmidt, J. A. & Trepel, M. (2009). Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS ONE 4, e5122.
21. Mingozzi, F. & High, K. A. (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12, 341-355.
22. Mitchell, A. M., Nicolson, S. C., Warischalk, J. K. & Samulski, R. J. (2010). AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther 10, 319-340.
23. Mueller, C. & Flotte, T. R. (2008). Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 15, 858-863.
24. Müller, O. J., Kaul, F., Weitzman, M. D., Pasqualini, R., Arap, W., Kleinschmidt, J. A. & Trepel, M. (2003). Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 21, 1040-1046.
25. Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O. J. & Kleinschmidt, J. A. (2012). Development and validation of novel AAV2 random libraries displaying peptides of diverse lengths and at diverse capsid positions. Hum Gene Ther 23, 492-507.
26. Nettelbeck, D. M., Rivera, A. A., Kupsch, J., Dieckmann, D., Douglas, J. T., Kontermann, R. E., Alemany, R. & Curiel, D. T. (2004). Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int J Cancer 108, 136-145.
27. Nonnenmacher, M. & Weber, T. (2012). Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther 19, 649-658.
28. Opie, S. R., Warrington, K. H., Jr, Agbandje-McKenna, M., Zolotukhin, S. & Muzyczka, N. (2003). Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 77, 6995-7006.
29. Perabo, L., Büning, H., Kofler, D. M., Ried, M. U., Girod, A., Wendtner, C. M., Enssle, J. & Hallek, M. (2003). In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 8, 151-157.
30. Perabo, L., Goldnau, D., White, K., Endell, J., Boucas, J., Humme, S., Work, L. M., Janicki, H., Hallek, M. & other authors (2006). Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol 80, 7265-7269.
31. Schaffer, D. V., Koerber, J. T. & Lim, K. I. (2008). Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng 10, 169-194.
32. Sonntag, F., Bleker, S., Leuchs, B., Fischer, R. & Kleinschmidt, J. A. (2006). Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol 80, 11040-11054.
33. Veldwijk, M. R., Topaly, J., Laufs, S., Hengge, U. R., Wenz, F., Zeller, W. J. & Fruehauf, S. (2002). Development and optimization of a realtime quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol Ther 6, 272-278.
34. Waterkamp, D. A., Müller, O. J., Ying, Y., Trepel, M. & Kleinschmidt, J. A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J Gene Med 8, 1307-1319.
35. Wistuba, A., Weger, S., Kern, A. & Kleinschmidt, J. A. (1995). Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J Virol 69, 5311-5319.
36. Yan, Z., Zak, R., Luxton, G. W., Ritchie, T. C., Bantel-Schaal, U. & Engelhardt, J. F. (2002). Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 76, 2043-2053.
37. Ying, Y., Müller, O. J., Goehringer, C., Leuchs, B., Trepel, M., Katus, H. A. & Kleinschmidt, J. A. (2010). Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther 17, 980-990.
38. Zhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A. & other authors (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381, 194-202.